Tanapong Watchararot

Dr. Tanapong Watchararot

Biomedical engineering, Chulalongkorn University, Bangkok, Krung Thep Maha Nakhon, Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Royal Society Open Science
Verified
Journal Article
Open access
TWTanapong Watchararot
Tanapong Watchararot
WPWeerapong Prasongchean
Weerapong Prasongchean
PTPeerapat Thongnuek
Peerapat Thongnuek
Angiogenesis is a crucial step in tissue regeneration and repair. Biomaterials that allow or promote angiogenesis are thus beneficial. In this study, angiogenic properties of salt-leached silk fibroin (SF) scaffolds seeded with human adipose stem cells (hADSCs) were studied using chick chorioallantoic membrane (CAM) as a model. The hADSC-seeded SF scaffolds (SF-hADSC) with the porosity of 77.34 ± 6.96% and the pore diameter of 513.95 ± 4.99 µm were implanted on the CAM of chick embryos that were on an embryonic day 8 (E8) of development. The SF-hADSC scaffolds induced a spoke-wheel pattern of capillary network indicative of angiogenesis, which was evident since E11. Moreover, the ingrowth of blood vessels into the scaffolds was seen in histological sections. The unseeded scaffolds induced the same extent of angiogenesis later on E14. By contrast, the control group could not induce the same extent of angiogenesis. In vitro cytotoxicity tests and in vivo angioirritative study reaffirmed the biocompatibility of the scaffolds. This work highlighted that the biocompatible SF-hADSC scaffolds accelerate angiogenesis, and hence they can be a promising biomaterial for the regeneration of tissues that require angiogenesis.

28 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PJPhatsawee Jansook
Phatsawee Jansook
HSHay Man Saung Hnin Soe
Hay Man Saung Hnin Soe
RARathapon Asasutjarit
Rathapon Asasutjarit
TTTheingi Tun
Theingi Tun
HHHay Marn Hnin
Hay Marn Hnin
TLThorsteinn Loftsson
Thorsteinn Loftsson
Celecoxib (CCB), a cyclooxygenase-2 inhibitor, is capable of reducing oxidative stress and vascular endothelial growth factor (VEGF) expression in retinal cells and has been shown to be effective in the treatment of diabetic retinopathy and age-related macular degeneration. However, the ocular bioavailability of CCB is hampered due to its very low aqueous solubility. In a previous study, we developed 0.5% (w/v) aqueous CCB eye drop microsuspensions (MS) containing randomly methylated β-cyclodextrin (RMβCD) or γ-cyclodextrin (γCD) and hyaluronic acid (HA) as ternary CCB/CD/HA nanoaggregates. Both formulations exhibited good physicochemical properties. Therefore, we further investigated their cytotoxicity and efficacy in a human retina cell line in this study. At a CCB concentration of 1000 μg/mL, both CCB/RMβCD and CCB/γCD eye drop MS showed low hemolysis activity (11.1 ± 0.3% or 4.9 ± 0.2%, respectively). They revealed no signs of causing irritation and were nontoxic to retinal pigment epithelial cells. Moreover, the CCB eye drop MS exhibited significant anti-VEGF activity by reducing VEGF mRNA and protein levels compared to CCB suspended in phosphate buffer saline. The ex vivo transscleral diffusion demonstrated that a high quantity of CCB (112.47 ± 37.27 μg/mL) from CCB/γCD eye drop MS was deposited in the porcine sclera. Our new findings suggest that CCB/CD eye drop MS could be safely delivered to the ocular tissues and demonstrate promising eye drop formulations for retinal disease treatment.

9 April 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TWTanapong Watchararot
Tanapong Watchararot
NSNopparuj Soomherun
Nopparuj Soomherun
JJJirasak Jitpibull
Jirasak Jitpibull
SKSaran Keeratihattayakorn
Saran Keeratihattayakorn
JRJuthamas Ratanavaraporn
Juthamas Ratanavaraporn